BCL2L1 and meningioma: In this study, the combination of everolimus and gemcitabine sensitized malignant meningioma cells to A-1331852 and A-1155463, specific inhibitors of BCL-xL, but not to venetoclax, a specific inhibitor of BCL-2, suggesting that sensitization effects were mainly dependent on the inhibition of BCL-xL.